While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

I tried four vibe-coding tools, including Cursor and Replit, with no coding background. Here's what worked (and what didn't).

Replit’s new feature generates iOS apps from text prompts, integrates monetization, and streamlines App Store publishing - ...

In this tutorial, we use GlowScript VPython to build a dipole electric field simulation step by step. Learn how to model charges, compute field vectors, and create an interactive visualization that ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

Currently, the Python extension only supports “Run Selection/Line in Native Python REPL”. However, there is no built-in command to run the entire file in the Native Python REPL environment, similar to ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

Kara Alaimo is an associate professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...